Lintuzumab Ac-225 - Actinium Pharmaceuticals

Drug Profile

Lintuzumab Ac-225 - Actinium Pharmaceuticals

Alternative Names: 225Ac-HuM-195; 225Ac-lintuzumab; AC225 MOAB M195; Ac225 monoclonal antibody M195; Actimab-A; Actimab-M; Actimab-MDS; Actinium-225 (225Ac)-Lintuzumab; Actinium-225-labelled HuM195; HuM195-Ac-225

Latest Information Update: 04 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PDL BioPharma
  • Developer Actinium Pharmaceuticals; Baylor Research Institute; Medical College of Wisconsin; Memorial Sloan-Kettering Cancer Center; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Phase I Multiple myeloma

Most Recent Events

  • 28 Jun 2018 Actinium Pharmaceuticals initiates enrolment in a clinical trial for Acute myeloid leukaemia in USA
  • 22 May 2018 Phase-I clinical trials in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT03441048)
  • 13 Mar 2018 US FDA approves IND application for Lintuzumab Ac-225 in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top